Marcus O. Butler, MD, of Toronto’s Princess Margaret Cancer Centre, discusses evidence of tumor response in orbital lesions treated with tebentafusp in patients with metastatic uveal melanoma. Tebenta...
Lindsay L. Peterson, MD, of the Washington University, St. Louis, discusses the value of physical activity in improving cancer prognosis, especially for patients with breast or colon cancer. Aerobic e...
Carmen E. Guerra, MD, MSCE, of the University of Pennsylvania Abramson Cancer Center, discusses the ways in which community outreach, programs to help patients access cancer clinical trials, and insti...
Dario A. Vignali, PhD, of the University of Pittsburgh School of Medicine, discusses LAG3, the third inhibitory receptor to be used in the clinic. He describes the signaling mechanism this immunothera...
Jeffrey S. Weber, MD, PhD, of the Perlmutter Cancer Center at New York University Langone, discusses efficacy and safety results from the phase II KEYNOTE-942 trial, which showed that a personalized m...
Christina M. Dieli-Conwright, PhD, MPH, of Dana-Farber Cancer Institute, discusses her research on the ways in which postdiagnosis exercise, particularly resistance exercise, can build strength and mu...
R. Katie Kelley, MD, of the Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco, discusses phase III findings of the KEYNOTE-966 study, which showed that add...
Harry Klein, PhD, of Dana-Farber Cancer Institute, discusses MatchMiner, a software platform launched in 2017, that matches patients with appropriate clinical trials of targeted therapies. The platfor...
Karriem S. Watson, DHSc, MPH, of the National Institutes of Health All of Us Research Program, discusses the importance of engaging in clinical trials for those who are underrepresented in biomedical ...
Sherry X. Yang, MD, PhD, of the National Cancer Institute, discusses findings from the TAILORx trial, which showed that, despite chemotherapy, patients with high recurrence scores continue to have a p...
Timothy A. Yap, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses safety and efficacy data on three different PARP inhibitors combined with the ATR inhibitor camonsertib in pati...
Pierce K.H. Chow, PhD, MBBS, of the National Cancer Centre, Singapore and Duke-NUS Medical School, discusses phase III findings showing that, for patients with hepatocellular carcinoma at high risk of...
Diana Azzam, PhD, of Florida International University, Robert Stempel College of Public Health and Social Work, discusses her study results, which showed that treatment protocols guided by functional ...
Sherry X. Yang, MD, PhD, of the National Cancer Institute, discusses findings from the TAILORx trial, which showed that, despite chemotherapy, patients with high recurrence scores continue to have a p...
John V. Heymach, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses phase III results from the AEGEAN trial, which showed that patients with treatment-naive, resectable, non–smal...